CCM
ALNY icon

Copernicus Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Copernicus Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,000
Closed -$260K – 15
2020
Q4 		$260K Buy
+2,000
New +$267K 4.05% 14

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Copernicus Capital Management's ALNY Position: Q1 2021 in Review

Copernicus Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2021, closing a stake of 2,000 shares — an estimated $260K sold.

Copernicus Capital Management first reported a position in ALNY in Q4 2020 and held it in 1 quarter. The position peaked at $260K in Q4 2020. 390 funds tracked by Wall St. Rank hold ALNY as of Q1 2021.

  • Copernicus Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Copernicus Capital Management sold 2,000 Alnylam Pharmaceuticals shares in Q1 2021, an estimated $260K.
  • Copernicus Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Copernicus Capital Management's Alnylam Pharmaceuticals position peaked at $260K in Q4 2020.
  • 390 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2021.

Based on Copernicus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.